EDWARD S. WONG, M.D.; MARY McKEVITT, R.N., B.S.; KATE RUNNING, P.A., W.H.C.S.; GEORGE W. COUNTS, M.D.; MARVIN TURCK, M.D.; WALTER E. STAMM, M.D.
In a randomized crossover trial, 38 women with recurrent urinary tract infections were assigned to use either continuous prophylaxis with trimethoprim-sulfamethoxazole or intermittent self-administered therapy (single-dose trimethoprim-sulfamethoxazole taken for acute urinary symptoms). The infection rate for patients on prophylaxis was 0.2 episodes/patient-year compared with 2.2 infections/patient-year for patients on self-administered therapy (p < 0.001). Thirty-five of thirty-eight symptomatic episodes diagnosed by patients as infection were confirmed microbiologically, and 30 of the 35 infections responded clinically and microbiologically to patient-administered therapy with single-dose trimethoprim-sulfamethoxazole. No complications were seen in the 5 patients in whom therapy failed. The annual costs of prophylaxis and self-therapy were similar ($256 and $239, respectively) and both were less expensive than conventional therapy in women having 2 or more infections per year. In selected women, self-therapy is efficacious and economical compared with conventional therapy or prophylaxis.
WONG ES, McKEVITT M, RUNNING K, COUNTS GW, TURCK M, STAMM WE. Management of Recurrent Urinary Tract Infections with Patient-Administered Single-Dose Therapy. Ann Intern Med. ;102:302–307. doi: 10.7326/0003-4819-102-3-302
Download citation file:
Published: Ann Intern Med. 1985;102(3):302-307.
Infectious Disease, Nephrology, Urinary Tract Infection, Urological Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use